Pharmacovigilance World 2023
Wednesday, November 1, 2023 -- Thursday, November 2, 2023, 0830 - 1730
The Pharmacovigilance World 2023 conference will provide a platform for the participants to discuss, share and stay updated with present state of affairs in Pharmacovigilance and Drug safety, and how it contributes to the public health. It will also allow all its participants to interact with the experts, discuss the various developments, challenges faced and innovations in the field. Our Pharmacovigilance conferences are known for bringing the world-class leaders together to connect, learn and network. The conference will bring-forth the participants and the representatives from various fields of pharmacovigilance and drug safety under a common umbrella, and will provide them an opportunity to network with various industry professionals including pharmaceuticals, biologics, devices, CROs and PV service providers.
With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in the recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, the drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment methods and drugs. However, evidence suggests though avoidable, the adverse drug reactions (ADRs) to medicines continue to be the bigger life risk. In England, ADR was responsible for up to 6% of hospital admissions, carrying a mortality of 2% and costing the NHS £466 million per annum (€654 million, US$ 602 million) in 2004. In some countries, ADR is ranked among the top 10 leading causes of mortality. The concept of drug safety and pharmacovigilance has evolved considerably and is highly necessary to keep the severity of ADR under check. In order to prevent or to reduce harm to patients and improve public health, it is vital to develop and practice mechanisms for evaluating and monitoring the safety of medicines in clinical use. Pharmacovigilance briefs the potential implications of such trends on the evolution of science.
However, these days it is confronting issues to develop a better health care system in this global pitch. Some of the major challenges include globalization, web-based sales and information, broader safety concerns, public health versus pharmaceutical industry economic growth, monitoring of established products, developing and emerging countries, attitudes and perceptions to benefit and harm, outcomes and impact, etc.
Key Highlights:
Pharmacovigilance and globalization
Pharmacovigilance in a pandemic world
Women and child health care medicines and pharmacovigilance
Patient-centric approaches in PV
Pharmacovigilance legislation and regulations
Harmonization and pharmacovigilance
Advanced therapeutic techniques and pharmacovigilance
Pharmacovigilance and data management and eudravigilance
Post-marketing surveillance in pharmacovigilance
PV regulations and challenges
Benefit-risk management strategies
Risk management and minimization
Risk Evaluation and Mitigation
Adverse drug reactions reporting
Signal detection and post authorization safety
Good Pharmacovigilance Practices
Innovative approaches to drug safety
Strategies to improve PV
Real World Evidence in PV
Big data and AI in pharmacovigilance
Pharmacovigilance Workflows with AI & Automation
Other emerging technologies in PV
Who should attend the conference?
Attendees includes Chief Data Officer, VPs, GMs, Directors, Heads and Managers of
Pharmacovigilance
Safety & Risk management
Drug safety
PV Compliance
Safety Surveillance
Medical Affairs
Regulatory Affairs
Inspection and Audit
Pharmacoepidemiology
Post-market studies
Medical product safety assessment
Drug Research & Development
Clinical Pharmacology
Medical information
Contract outsourcing service providers
Health outcomes
Sales and Marketing
Post-market studies
Medical product safety assessment
Drug Research & Development
Clinical Pharmacology
Medical information
Contract outsourcing service providers
Health outcomes
Sales and Marketing
With the augmented incidence of diseases, and the non-medical use of prescription drugs, the incidence of drug abuse has increased enormously in the recent years, which is apparent with the excess documentation of adversities and drug toxicities. In this context, the drug safety and pharmacovigilance has emerged as a dynamic clinical and scientific discipline to provide adequate information and ensure health safety by the joint interaction of doctors and patients in choosing appropriate treatment methods and drugs. However, evidence suggests though avoidable, the adverse drug reactions (ADRs) to medicines continue to be the bigger life risk. In England, ADR was responsible for up to 6% of hospital admissions, carrying a mortality of 2% and costing the NHS £466 million per annum (€654 million, US$ 602 million) in 2004. In some countries, ADR is ranked among the top 10 leading causes of mortality. The concept of drug safety and pharmacovigilance has evolved considerably and is highly necessary to keep the severity of ADR under check. In order to prevent or to reduce harm to patients and improve public health, it is vital to develop and practice mechanisms for evaluating and monitoring the safety of medicines in clinical use. Pharmacovigilance briefs the potential implications of such trends on the evolution of science.
However, these days it is confronting issues to develop a better health care system in this global pitch. Some of the major challenges include globalization, web-based sales and information, broader safety concerns, public health versus pharmaceutical industry economic growth, monitoring of established products, developing and emerging countries, attitudes and perceptions to benefit and harm, outcomes and impact, etc.
Key Highlights:
Pharmacovigilance and globalization
Pharmacovigilance in a pandemic world
Women and child health care medicines and pharmacovigilance
Patient-centric approaches in PV
Pharmacovigilance legislation and regulations
Harmonization and pharmacovigilance
Advanced therapeutic techniques and pharmacovigilance
Pharmacovigilance and data management and eudravigilance
Post-marketing surveillance in pharmacovigilance
PV regulations and challenges
Benefit-risk management strategies
Risk management and minimization
Risk Evaluation and Mitigation
Adverse drug reactions reporting
Signal detection and post authorization safety
Good Pharmacovigilance Practices
Innovative approaches to drug safety
Strategies to improve PV
Real World Evidence in PV
Big data and AI in pharmacovigilance
Pharmacovigilance Workflows with AI & Automation
Other emerging technologies in PV
Who should attend the conference?
Attendees includes Chief Data Officer, VPs, GMs, Directors, Heads and Managers of
Pharmacovigilance
Safety & Risk management
Drug safety
PV Compliance
Safety Surveillance
Medical Affairs
Regulatory Affairs
Inspection and Audit
Pharmacoepidemiology
Post-market studies
Medical product safety assessment
Drug Research & Development
Clinical Pharmacology
Medical information
Contract outsourcing service providers
Health outcomes
Sales and Marketing
Post-market studies
Medical product safety assessment
Drug Research & Development
Clinical Pharmacology
Medical information
Contract outsourcing service providers
Health outcomes
Sales and Marketing
Starting Price Per Person
£ 527.00 GBP
Other Information
Where
London United Kingdom
Kensington High St
London W8 5SP
United Kingdom
( Hotel - Resort )
Kensington High St
London W8 5SP
United Kingdom
( Hotel - Resort )
Event Organizer Contact
More Events
Event ID: 217589
Get Events in Your Inbox
We have over 100,000 Events in 80+ Categories. Tell us what type of events you like, and we will send them to your inbox